Multiple Sclerosis Treatments Affect Monocyte-Derived Microvesicle Production
Microvesicles (MVs) are released by immune cells especially of the myeloid lineage upon stimulation with ATP on its cognate receptor P2X7, both in physiological and pathological conditions. In multiple sclerosis (MS) the role of MVs remains little investigated. We aimed to compare the release of MVs...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2017-08-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fneur.2017.00422/full |
| _version_ | 1819003776162332672 |
|---|---|
| author | Maria Blonda Antonella Amoruso Roberta Grasso Valeria Di Francescantonio Carlo Avolio |
| author_facet | Maria Blonda Antonella Amoruso Roberta Grasso Valeria Di Francescantonio Carlo Avolio |
| author_sort | Maria Blonda |
| collection | DOAJ |
| description | Microvesicles (MVs) are released by immune cells especially of the myeloid lineage upon stimulation with ATP on its cognate receptor P2X7, both in physiological and pathological conditions. In multiple sclerosis (MS) the role of MVs remains little investigated. We aimed to compare the release of MVs in peripheral blood monocytes from MS patients with healthy donors (HDs) and to see how current MS treatment may affect such a production. We also assessed the treatment effect on M1 and M2 monocyte polarization and on the inflammasome components. Spectrophotometric quantification was performed to compare monocyte-derived MVs from 20 untreated relapsing-remitting MS patients and 20 HDs and to evaluate the effect of different treatments. Subgroups of nine interferon-beta and of five teriflunomide-treated MS patients were evaluated at baseline and after 2, 6, and 12 months of treatment. Six MS patients taking Fingolimod, after switching from a first-line therapy, were included in the study and analyzed only at 12 months of treatment. MVs analysis revealed that monocytes from MS patients produced vesicles in higher amounts than controls. All treatments reduced vesicle production but only teriflunomide was associated with a downregulation of purinergic P2X7 receptor and inflammasome components expression. The therapies modulated mRNA expression of both M1 and M2 monocyte markers. Our results, suggesting new molecular targets for drugs currently used in MS, may potentially provide useful novel evidence to approach the disease. |
| first_indexed | 2024-12-20T23:26:22Z |
| format | Article |
| id | doaj.art-dc6b45e8a0404b96a0a64692f6323fe8 |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-12-20T23:26:22Z |
| publishDate | 2017-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-dc6b45e8a0404b96a0a64692f6323fe82022-12-21T19:23:23ZengFrontiers Media S.A.Frontiers in Neurology1664-22952017-08-01810.3389/fneur.2017.00422267009Multiple Sclerosis Treatments Affect Monocyte-Derived Microvesicle ProductionMaria Blonda0Antonella Amoruso1Roberta Grasso2Valeria Di Francescantonio3Carlo Avolio4Department of Medical and Surgical Sciences, University of Foggia, Foggia, ItalyDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, ItalyDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, ItalyDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, ItalyDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, ItalyMicrovesicles (MVs) are released by immune cells especially of the myeloid lineage upon stimulation with ATP on its cognate receptor P2X7, both in physiological and pathological conditions. In multiple sclerosis (MS) the role of MVs remains little investigated. We aimed to compare the release of MVs in peripheral blood monocytes from MS patients with healthy donors (HDs) and to see how current MS treatment may affect such a production. We also assessed the treatment effect on M1 and M2 monocyte polarization and on the inflammasome components. Spectrophotometric quantification was performed to compare monocyte-derived MVs from 20 untreated relapsing-remitting MS patients and 20 HDs and to evaluate the effect of different treatments. Subgroups of nine interferon-beta and of five teriflunomide-treated MS patients were evaluated at baseline and after 2, 6, and 12 months of treatment. Six MS patients taking Fingolimod, after switching from a first-line therapy, were included in the study and analyzed only at 12 months of treatment. MVs analysis revealed that monocytes from MS patients produced vesicles in higher amounts than controls. All treatments reduced vesicle production but only teriflunomide was associated with a downregulation of purinergic P2X7 receptor and inflammasome components expression. The therapies modulated mRNA expression of both M1 and M2 monocyte markers. Our results, suggesting new molecular targets for drugs currently used in MS, may potentially provide useful novel evidence to approach the disease.http://journal.frontiersin.org/article/10.3389/fneur.2017.00422/fullmultiple sclerosismicrovesiclesmonocytesdisease modifying drugsInferferon betaTeriflunomide |
| spellingShingle | Maria Blonda Antonella Amoruso Roberta Grasso Valeria Di Francescantonio Carlo Avolio Multiple Sclerosis Treatments Affect Monocyte-Derived Microvesicle Production Frontiers in Neurology multiple sclerosis microvesicles monocytes disease modifying drugs Inferferon beta Teriflunomide |
| title | Multiple Sclerosis Treatments Affect Monocyte-Derived Microvesicle Production |
| title_full | Multiple Sclerosis Treatments Affect Monocyte-Derived Microvesicle Production |
| title_fullStr | Multiple Sclerosis Treatments Affect Monocyte-Derived Microvesicle Production |
| title_full_unstemmed | Multiple Sclerosis Treatments Affect Monocyte-Derived Microvesicle Production |
| title_short | Multiple Sclerosis Treatments Affect Monocyte-Derived Microvesicle Production |
| title_sort | multiple sclerosis treatments affect monocyte derived microvesicle production |
| topic | multiple sclerosis microvesicles monocytes disease modifying drugs Inferferon beta Teriflunomide |
| url | http://journal.frontiersin.org/article/10.3389/fneur.2017.00422/full |
| work_keys_str_mv | AT mariablonda multiplesclerosistreatmentsaffectmonocytederivedmicrovesicleproduction AT antonellaamoruso multiplesclerosistreatmentsaffectmonocytederivedmicrovesicleproduction AT robertagrasso multiplesclerosistreatmentsaffectmonocytederivedmicrovesicleproduction AT valeriadifrancescantonio multiplesclerosistreatmentsaffectmonocytederivedmicrovesicleproduction AT carloavolio multiplesclerosistreatmentsaffectmonocytederivedmicrovesicleproduction |